DAX19.315 +0,9%ESt504.788 +0,7%MSCIW3.760 +0,2%Dow44.115 +0,6%Nas18.946 -0,1%Bitcoin93.510 -0,6%Euro1,0413 -0,6%Öl74,67 +0,4%Gold2.696 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Tesla A1CX3T Rheinmetall 703000 Bayer BAY001 Siemens Energy ENER6Y Amazon 906866 Volkswagen (VW) vz. 766403 Coinbase A2QP7J NEL ASA A0B733 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Telekom 555750 EVOTEC 566480 Palantir A2QA4J Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX zieht an -- Wall Street fester -- Bitcoin knapp vor 100.000 US-Dollar -- VW drohen Warnstreiks ab Anfang Dezember -- Chef der US-Börsenaufsicht tritt ab -- RWE, Secunet, NEL im Fokus
Top News
S&P 500-Titel Meta Platforms (ex Facebook)-Aktie: So viel Gewinn hätte ein Investment in Meta Platforms (ex Facebook) von vor 3 Jahren eingefahren S&P 500-Titel Meta Platforms (ex Facebook)-Aktie: So viel Gewinn hätte ein Investment in Meta Platforms (ex Facebook) von vor 3 Jahren eingefahren
S&P 500-Wert Berkshire Hathaway-Aktie: So viel hätten Anleger mit einem Investment in Berkshire Hathaway von vor einem Jahr verdient S&P 500-Wert Berkshire Hathaway-Aktie: So viel hätten Anleger mit einem Investment in Berkshire Hathaway von vor einem Jahr verdient
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

INNATE PHARMA SA Aktie

NeuKaufenVerkaufen
1,51 EUR ±0,00 EUR +0,27 %
STU
1,53 EUR -0,06 EUR -3,54 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.128,22 Mio. EUR

Div. Rendite0,00%

WKNA0LCUJ

ISINFR0010331421

SymbolIPHYF

INNATE PHARMA SA Aktien News

DatumMeistgelesen
BusinesswireInnate Pharma Releases Its 2025 Financial Calendar
BusinesswireInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
BusinesswireInnate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Wer­bungINNATE PHARMA SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BusinesswireInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
BusinesswireInnate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conferences
BusinesswireInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
BusinesswireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
BusinesswireInnate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
BusinesswireInnate Pharma Reports First Half 2024 Business Update and Financial Results
BusinesswireInnate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
BusinesswireInnate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
BusinesswireInnate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conference
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of July 10, 2024
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of June 10, 2024
BusinesswireInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
BusinesswireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conferences
BusinesswireInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
BusinesswireOutcome of Innate Pharma’s 2024 Annual General Meeting
BusinesswireInnate Pharma: Clarification Regarding SAR443579 Designation
BusinesswireInnate Pharma Highlights Abstracts Selected for EHA 2024 Congress
BusinesswireInnate Pharma Reports First Quarter 2024 Business Update and Financial Results
BusinesswireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
BusinesswireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
BusinesswireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
BusinesswireInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conference
BusinesswireInnate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
BusinesswireInnate Pharma Reports Full Year 2023 Financial Results and Business Update
BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conference
BusinesswireInnate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
BusinesswireInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
BusinesswireInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conference
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of January 1, 2024
BusinesswireInnate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
BusinesswireInnate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
BusinesswireInnate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

INNATE PHARMA SA News

INNATE PHARMA SA News: auf dieser Seite finden Sie alle INNATE PHARMA SA News und Nachrichten zur INNATE PHARMA SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch INNATE PHARMA SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um INNATE PHARMA SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.